Skip to main content

Table 2 Incidence and duration of secondary outcomes within 60 days of hematopoietic stem cell transplantation in the two groups of study patients

From: Effect of vitamin A on intestinal mucosal injury in pediatric patients receiving hematopoietic stem cell transplantation and chemotherapy: a quasai-randomized trial

Outcomes

Study groups

P value

Vitamin A supplementation (n = 15)

Non-vitamin A supplementation (n = 15)

Febrile neutropenia, n (%)

11 (73.3)

11 (73.3)

1

Oral mucositis, n (%)

14 (93.3)

15 (100)

1

Oral mucositis severity grade 3–4, n (%)

6 (40)

9 (60)

0.27

Diarrhea, n (%)

14 (93.3)

14 (93.3)

1

Hemorrhagic cystitis, n (%)

5 (33.3)

5 (33.3)

1

Graft-versus-host disease, n (%)

6 (40)

7 (46.7)

1

Bacterial infection, n (%)

1 (6.7)

2 (13.3)

1

Viral infection, n (%)

10 (66.7)

6 (40)

0.14

Day of neutrophil engraftment, mean days ± SD

14 ± 2.8

14.2 ± 3.9

0.87

Duration of febrile neutropeniaa, days

5 (2–10)

6.5 (1–21)

0.8

Duration of mucositis, mean days ± SD

9 ± 3.8

9 ± 4.7

0.96

Duration of diarrheaa, days

11.5 (2–44)

15.5 (2–37)

0.42

Duration of need of TPN, days ± SD

13 ± 7.1

11 ± 6.6

0.42

Duration of hospitalization after day 0a, days

29 (18–83)

24 (15–54)

0.13

Mortality, n (%)

0

2 (13.3)

0.48

  1. aMedian (min–max)
  2. SD standard deviation, TPN total parenteral nutrition